AMGN News 127.34 08/14/2014 04:32:25 Amgen Inc (AMGN)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Amgen Inc (AMGN) 127.34 $AMGN

Growth Factors (Blood and Tissue) Market 2014 - Global Strategic Business Report
M2 - 1 hr 38 mins ago
Research and Markets (http://www.researchandmarkets.com/research/bqzzts/growth_factors) has announced the addition of the "Growth Factors (Blood and Tissue) - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Growth Factors (Blood and Tissue) in US$ Million by the following Types: - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, & Interleukins) - Tissue Growth Factors. The report profiles 90 companies including many key and niche players such as: - Alseres Pharmaceuticals, Inc. - Amgen, Inc. - Bayer HealthCare Pharmaceuticals, Inc. - Biogen Idec Inc - BioMimetic Therapeutics, Inc. - Biopharm GmbH - Bolder Biotechnology, Inc. - F. Hoffmann-La Roche Ltd - Chugai Pharmaceutical Co. Ltd. - Genentech, Inc. - FibroGen, Inc. - Johnson & Johnson - Janssen Biotech, Inc. - Lonza Group - Merck Serono International S.A. - NsGene A/S - PeproTech, Inc. - Reliance GeneMedix Plc - Sangamo BioSciences, Inc. - Sanofi - Shantha Biotechnics - Scil Proteins GmbH - Wockhardt Ltd. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Market Overview 2. Growth Factors An Overview 3. Research Studies & Clinical Trials 4. Product Innovations/Introductions 5. Recent Industry Activity 6. Focus On Select Players 7. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 90 (including Divisions/Subsidiaries 95) - The United States (42) - Japan (8) - Europe (19) - France (1) - Germany (8) - The United Kingdom (1) - Rest of Europe (9) - Asia-Pacific (Excluding Japan) (24) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/bq...th_factors

Why Amgen, Inc.’s Kyprolis FOCUS Failure Is a Big Deal
Brian Orelli, The Motley Fool - Motley Fool - Wed Aug 13, 7:52PM CDT
Source: Amgen Amgen 's Kyprolis has passed multiple clinical trials, but the failure today will overshadow the rest. That's because the only thing that really matters to cancer patients is survival. Does the drug help the patient live longer?...

AMGEN
at Investor's Business Daily - Wed Aug 13, 5:58PM CDT
AMGEN (AMGN) fell 2.1% in late trading after its Onyx subsidiary announced disappointing results from a late-stage trial of skin-cancer treatment Kyprolis vs. standard treatment.

Final Glance: Biotechnology companies
AP - Wed Aug 13, 5:14PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:

Amgen Issues Voluntary Recall of Aranesp® (darbepoetin alfa) (500 mcg) Prefilled Syringes in Several Countries Outside of the United States Due to the Presence of Visible Particulates
PR Newswire - Wed Aug 13, 3:12PM CDT
Amgen (NASDAQ:AMGN) initiated a voluntary recall on June 26, 2014 for nine packaged lots of Aranesp® (darbepoetin alfa) (500 mcg) prefilled syringes from non-U.S. distributors, wholesalers and a number of hospital pharmacies due to the potential presence of cellulose and/or polyester particles observed in a small number of syringes during a routine quality examination. Lots 1042847, 1044141A, 1044141C, 1044141D, 1046891A, 1046891B, 1047394A, 1047622A, and 1047996A are being recalled as a precautionary measure. To date, there have been no complaints or adverse events reported that can be attributed to the presence of these particles. Evaluations by Amgen found a very low potential to impact patients who may have received the affected product.

Amgen Announces Top-Line Results From Phase 3 Focus Trial Of Kyprolis® In Patients With Relapsed And Advanced Refractory Multiple Myeloma
PR Newswire - Wed Aug 13, 3:01PM CDT
Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that the Phase 3 clinical trial FOCUS (CarFilzOmib for AdvanCed Refractory MUltiple Myeloma European Study) did not meet its primary endpoint of improving overall survival (OS) (HR=0.975, 95 percent CI, 0.760, 1.249). The 315-patient, open-label study evaluated single-agent Kyprolis® (carfilzomib) for Injection compared to an active control regimen of low-dose dexamethasone, or equivalent corticosteroids, plus optional cyclophosphamide in patients with relapsed and advanced refractory multiple myeloma. Nearly all patients in the control arm received cyclophosphamide. Patients were heavily pretreated and had received a median of five therapeutic regimens prior to study entry.

Midday Glance: Biotechnology companies
AP - Wed Aug 13, 12:50PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:

Early Glance: Biotechnology companies
AP - Wed Aug 13, 9:32AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:

UBS AG Contemplates $4.5B Bond Offerings in U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 4:05PM CDT
As per Bloomberg, the Swiss major UBS AG (UBS) is planning corporate bond offerings in the U.S. The bank will be issuing $4.5 billion worth of bonds.

Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020
PR Newswire Europe - Tue Aug 12, 12:50PM CDT
DUBLIN, Aug. 12, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/kpr76z/biological_drugs] has announced the addition of the "Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" [http://www.researchandmarkets.com/research/kpr76z/biological_drugs] report to their offering.

Amgen Up 8.6% Since SmarTrend Uptrend Call (AMGN)
Comtex SmarTrend(R) - Tue Aug 12, 9:27AM CDT
SmarTrend identified an Uptrend for Amgen (NASDAQ:AMGN) on June 2nd, 2014 at $116.45. In approximately 2 months, Amgen has returned 8.57% as of today's recent price of $126.43.

5 Things Amgen, Inc.'s Management Wants You to Know
Sean Williams, The Motley Fool - Motley Fool - Mon Aug 11, 3:25PM CDT
Amgen reported its second-quarter earnings results two weeks ago, delivering yet another quarter of impressive growth and boosting full-year guidance. Source: University of Michigan School of Natural Resources & Environment , Flickr. ...

Investors Applaud Amgen and Novartis for Support of Investor Principles on Biosimilars, Alternatives to Higher Cost Drugs
PR Newswire - Mon Aug 11, 12:07PM CDT
A coalition of 19 institutional investors representing $430 billion in assets commends Amgen and Novartis for support of a set of investor principles to guide corporate boards on policy and oversight responsibilities related to biosimilar activities. The principles, included in the coalition's Investor Statement on Board Oversight of Biosimilar Issues, call on boards to ensure that information provided to policymakers on patient safety is balanced, investor dollars used for political lobbying is aligned with shareholder interests, and disclosure on significant business partnerships is transparent. Biosimilars are biologic medical products whose active drug substance is derived from a living organism and used to treat serious illnesses including cancer, rheumatoid arthritis, and multiple sclerosis.

Earnings Flashback: Since Reporting Quarterly Results 1 Week Ago Amgen Is Up 3.0% (AMGN)
Comtex SmarTrend(R) - Mon Aug 11, 12:02PM CDT
A week ago on July 29th, 2014 Amgen (NASDAQ:AMGN) reported earnings and analysts, on average, expected earnings of $2.07 on sales of $4.9 billion. The company actually reported EPS of $2.37 on sales of $5.2 billion, beating EPS estimates by $0.30 and beating revenue estimates by $279.7 million. Shares of Amgen have climbed from $123.31 to $126.95, representing a gain of 3.0% since the company reported earnings 13 days ago.

Amgen Receives CEO Cancer Gold Standard Accreditation
Business Wire - Mon Aug 11, 6:00AM CDT
The CEO Roundtable on Cancer today announced that Amgen, Inc., one of the world's leading biotechnology companies, has received CEO Cancer Gold Standard(TM) accreditation. This achievement recognizes employers' commitment to reducing cancer risk by promoting healthy lifestyle choices, encouraging early detection through cancer screenings, and ensuring access to quality treatment for employees and covered family members.

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Aug 08, 7:15PM CDT
Cramer's watching earnings next week as he seeks stocks worth buying, not selling, in this market.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Swell Partners' Awards Highlight Culture, Not Metrics

Updated Category News Views 65

Recognition Lands in a Crowded Talent Market Two shiny Stevie trophies do not pay payroll, but they can say something useful about a company trying to stand out in the noisy talent-services business. Swell Partners has been named 2026 Company of the Year in Business Services and has seen founder and CEO Cari Gatto receive Best Female CEO of the Year. For a private firm...

Continue Reading
A. O. Smith's Sustainability Scorecard Has Real Teeth

Updated Category News Views 40

Numbers finally showed up wearing work boots in A. O. Smith’s latest sustainability report. The company says it beat every one of its three environmental targets, and the gaps were not the sort of rounding-error victories corporate communications teams love to polish until they shine. For investors following NYSE:AOS, that deserves a look—not a standing ovation, but a...

Continue Reading
Scientific Games Takes Big Buck Hunter to Lotteries

Updated Category News Views 33

A mounted arcade cabinet is an odd place to find lottery growth, yet Scientific Games may be onto something with its exclusive Big Buck Hunter licensing deal. Announced November 19, 2026, the arrangement lets the company carry a 26-year-old arcade franchise into U.S. and Canadian instant scratch games, Fast Play, draw games, digital products and second-chance promotions....

Continue Reading
Peñoles Locks In Solar Storage for Northern Mine Loads

Updated Category News Views 159

A mine never sleeps, which is why the battery matters more than the solar-panel headline. Peñoles has signed a 20-year power-supply agreement with Atlas Renewable Energy for a Coahuila project combining 269 MWp of solar generation with battery storage. The project is slated to begin operating in the first half of 2029 and is expected to provide roughly 550 GWh a year to...

Continue Reading
Pennsylvania Rebate Rules Matter Before Year-End Filing

Updated Category News Views 47

A missed rebate form can sting harder than most people expect, especially when a household has already spent the year watching property taxes, rent, groceries, and every other stubborn bill chew through fixed income. Pennsylvania’s Property Tax/Rent Rebate Program is not glamorous, and it is certainly not an investing story. It is, however, the kind of direct household...

Continue Reading
RMT’s 12.4% Discount Still Demands a Much Harder Look

Updated Category News Views 23

A $1.84 gap is staring RMT shareholders right in the face. As of October 31, 2026, Royce Micro-Cap Trust carried a net asset value of $14.82 per share while the market price sat at $12.98. That is roughly a 12.4% discount to NAV, and closed-end fund investors should never wave off a spread like that with a lazy shrug. It may be opportunity. It may also be the market...

Continue Reading
Implantica's U.S. Launch Arrives With Cash Still to Burn

Updated Category News Views 104

RefluxStop has finally stepped onto American soil, and that changes the conversation around Implantica in a very real way. FDA Premarket Approval arrived on August 20, then the first U.S. procedures were completed in early November at the University of Southern California. For a small medtech outfit, clearing that regulatory gate and getting actual patients treated are...

Continue Reading
Stanford Forum Puts Industrial AI in the Real World

Updated Category News Views 116

Factory Data Is Not a Free Lunch A factory dataset is worth precisely nothing if its owner cannot control it. That was the hard-nosed thread running through the ASI City Forum at Stanford on November 17: industrial AI is not just about smarter models or splashy chip announcements. It is about whether manufacturers will trust a system with proprietary operating data,...

Continue Reading
PARRIS Partners Earn 2026 Plaintiff Lawyer Recognition

Updated Category News Views 95

A $58.4 million jury number can make a courtroom sound like a slot machine, until the final settlement lands at $21 million. That gap is the part people ought to stare at before getting carried away by another plaintiff-lawyer honor roll. The Daily Journal has named PARRIS Law Firm partners Alexander R. Wheeler and Khail A. Parris to its 2026 Top Plaintiff Lawyers special...

Continue Reading
Dubai's 2028 Fire Congress Puts Global Safety Tech on Stage

Updated Category News Views 77

Fire engines, wildfires, dense towers, and AI are all colliding in Dubai's next big public-safety moment. The World Fire Congress has handed its 2028 host role to Dubai, making this the first time the biennial gathering of global fire and emergency-service leaders will land in the Middle East. That is not a quarterly earnings event, and nobody ought to pretend it is....

Continue Reading

Top 5 Most Recently Viewed Articles

Elisa and Sensofusion Launch Joint Drone Venture in Europe

Updated Category News Views 293

A Match Made Beneath the Clouds Woke up today thinking about the bizarre world of drones, and it looks like Elisa Corporation and Sensofusion Plc are paving a new path in the skies of Europe. The two firms have locked hands to form Masthead Oy, aimed at creating a bird’s-eye defense mechanism to manage the unruly swarm of drones buzzing around Finland and Estonia. The...

Continue Reading
Innovative Alfapump Use in Elective Hernia Repair Highlights Benefits

Updated Category News Views 191

Innovative Solutions for Managing Ascites Managing ascites is vital, especially for patients encountering surgical options. Ascites, characterized by the accumulation of fluid in the abdomen, often complicates surgical procedures like umbilical hernia repairs. A significant number, about 20%, of individuals suffering from ascites due to liver cirrhosis are affected by...

Continue Reading
Kibu Unveils Insightful Cybersecurity Threat Report Series

Updated Category News Views 152

Kibu Unveils New Cybersecurity Threat Report Series Today, Kibu has announced the launch of an insightful quarterly threat report series that focuses on emerging challenges in the realm of cybersecurity. This new initiative aims to provide security teams with valuable insights derived from real-world scenarios and case studies, fully equipping them to tackle the evolving...

Continue Reading
Baidu Faces Securities Fraud Lawsuit: Key Investor Alert

Updated Category News Views 99

Stormy Weather for Baidu Investors Digging through the latest on Baidu's (NASDAQ:BIDU) unsettling journey feels like watching a rerun of a soap opera you wish would just end. The company has been slapped with a class action lawsuit by The Law Offices of Frank R. Cruz, accusing them of pulling the wool over investors' eyes from November 18, 2025, to August 17, 2026....

Continue Reading
Forecasting Earnings: What to Expect from IGC Pharma

Updated Category News Views 133

IGC Pharma's Approaching Earnings Announcement IGC Pharma (AMEX: IGC) is poised to disclose its quarterly earnings soon. Investors are looking forward to understanding the company's financial health and how it positions itself for the future. In the lead-up, it's vital to grasp the expectations that analysts have set. Analyst Estimates and Earnings Predictions Experts in...

Continue Reading